

Keystone Symposia in Taos

Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics

Scientific Organizers:

Gary D. Wu, Perelman School of Medicine, University of Pennsylvania, USA

Scott Snapper, Boston Children's Hospital, USA

Judy H. Cho, Icahn School of Medicine at Mount Sinai, USA

Aida Habtezion, Stanford School of Medicine, USA


Inflammatory bowel diseases (IBD), which afflict millions of patients, are rapidly increasing in incidence world-wide in parallel with industrialization. Pathogenesis involves both host genetic as well environmental factors, with the most currently utilized therapeutics focusing on long-term host immunosuppression. Despite tremendous advances in our understanding of IBD genetics, the mucosal immune system, and environmental factors such as the gut microbiome, currently available therapeutic modalities for IBD remain suboptimal. The overall goal of this conference is to bring together world-class investigators and clinicians to discuss the latest scientific knowledge relevant to the pathogenesis of IBD and facilitate an interactive discussion to accelerate development of new opportunities to prevent and/or treat IBD. The specific aims of this conference are to: 1) Bring together a combination of clinical and basic investigators from both academia and industry to facilitate cross-disciplinary discussions focused on IBD; 2) Identify both opportunities and gaps in current knowledge in the pathogenesis of IBD important for the development of new diagnostics and therapeutics; and 3) Create a multidisciplinary environment that will inspire both young and established investigators by highlighting the currently available opportunities in IBD research. The anticipated outcome will be a better understanding of the advances and challenges in developing new therapies for patients with IBD.

Plenary Session Topics:

- Clinical Considerations of IBD – What's the Goal?
- Workshop 1: Host Factors in IBD
- Advances in the Genetics of IBD
- The Mucosal Immune System in IBD: Innate Immunity
- The Mucosal Immune System in IBD: Adaptive Immunity
- The Environment in IBD Pathogenesis (Microbiome)
- Workshop 2: Environmental Factors in IBD
- Barrier Function in IBD
- Translational Opportunities (Bench to Bedside and Back Again)
- New Technologies and Collaborations between Industry and Academia

Scholarship/Discounted Abstract Deadline: Sep 20, 2018; Abstract Deadline: Oct 16, 2018;
Discounted Registration Deadline: Nov 13, 2018

Visit www.keystonesymposia.org/19A2 for more details.



KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery
a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics (A2)

January 13-17, 2019 • Sagebrush Inn & Suites • Taos, New Mexico, USA

Scientific Organizers: Gary D. Wu, Scott Snapper, Judy H. Cho and Aida Habtezion

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: September 20, 2018 / Abstract Deadline: October 16, 2018 / Discounted Registration Deadline: November 13, 2018

SUNDAY, JANUARY 13

Arrival and Registration

MONDAY, JANUARY 14

Welcome and Keynote Address

Fiona M. Powrie, University of Oxford, UK
Gut Reactions: Immune Pathways in the Intestine in Health and Disease

Clinical Considerations of IBD—What's the Goal?

Gilaad Kaplan, University of Calgary, Canada
Clinical Epidemiology with the Rising Incidence of IBD associated with Industrialization

Dermot P. B. McGovern, Cedars-Sinai Medical Center, USA
Using Genomics to Explain the Clinical Heterogeneity of IBD

Séverine Vermeire, KU Leuven, Belgium
Current and Future Therapeutics with Companion Diagnostics in IBD

Sarah Valdez, USA
Short Talk: Patient Advocate: Living with IBD and the Hope for a Better Tomorrow

Short Talk(s) Chosen from Abstracts

Workshop 1: Host Factors in IBD

Short Talks Chosen from Abstracts

Advances in the Genetics of IBD

Judy H. Cho, Icahn School of Medicine at Mount Sinai, USA
Precision IBD and Population Differences in Innate Immunity

Jeffrey Barrett, Genomics plc, UK
Fine-Mapping Inflammatory Bowel Disease loci to Single-Variant Resolution

Ramnik Xavier, Massachusetts General Hospital and Broad Institute, USA
From IBD-associated Genotypes to Altered Cellular and Organismal Function

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, JANUARY 15

The Mucosal Immune System in IBD—Innate Immunity

Richard S. Blumberg, Brigham and Women's Hospital, USA
nKT Cells and IBD

Clara Abraham, Yale University, USA
Modulation of Innate Immune Responses by IBD-associated Genes

Gérard Eberl, Institut Pasteur, France
Innate Lymphoid Cells in Defense, Immunopathology and Immunotherapy

Gabriel Nuñez, University of Michigan, USA
Modeling Innate Immune Interactions with the Gut Microbiota as a Paradigm for IBD Pathogenesis

Short Talk(s) Chosen from Abstracts

The Mucosal Immune System in IBD—Adaptive Immunity

Kenneth Smith, University of Cambridge, UK
T-Cell Exhaustion, Co-Stimulation and Clinical Outcome in Autoimmunity and Infection

Vijay K. Kuchroo, Brigham and Women's Hospital, Harvard Medical School, USA
Phenotypes and Differentiation of Pathogenic Th17 Cells

Aida Habtezion, Stanford School of Medicine, USA
Trafficking and Immune Response in IBD

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, JANUARY 16

The Environment in IBD Pathogenesis (Microbiome)

Andreas J. Bäuml, University of California, Davis, USA
The Genesis of Dysbiosis in IBD: Functional Consequences

June L. Round, University of Utah, USA
The Role of Fungi in IBD

Andrew J.S. Macpherson, University of Bern, Switzerland
The Outer Mucus Layer Hosts a Distinct Intestinal Microbial Niche

David N. Cook, Seres Therapeutics, Inc., USA
A Novel Approach to Treating Active Ulcerative Colitis using Microbial Consortia

Short Talk(s) Chosen from Abstracts

Workshop 2: Environmental Factors in IBD

Short Talks Chosen from Abstracts

Barrier Function in IBD

Thaddeus S. Stappenbeck, Washington University School of Medicine, USA
The Intestinal Epithelium in IBD

Lora V. Hooper, University of Texas Southwestern Medical Center, USA
Microbiota-Immune System Interactions in the Intestine

Andrew T. Gewirtz, Georgia State University, USA
Impacting Intestinal Mucus Barrier via Diet and Microbiota

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, JANUARY 17

Translational Opportunities (Bench to Bedside and Back Again)

Gary D. Wu, Perelman School of Medicine, University of Pennsylvania, USA
Engineering the Gut Microbiome in IBD

Scott Snapper, Boston Children's Hospital, USA
Identifying Novel Immune Therapeutics through Studying Rare Diseases

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics (A2)

January 13-17, 2019 • Sagebrush Inn & Suites • Taos, New Mexico, USA

Scientific Organizers: Gary D. Wu, Scott Snapper, Judy H. Cho and Aida Habtezion

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: September 20, 2018 / Abstract Deadline: October 16, 2018 / Discounted Registration Deadline: November 13, 2018

Gregory C. Gibson, Georgia Institute of Technology, USA
Integrative Genomics in Discriminating IBD Disease Progression

Markus F. Neurath, University Hospital Erlangen, Germany
Bridging the Gap between IBD Pathogenesis and the Development of New Therapeutics

Short Talk(s) Chosen from Abstracts

New Technologies and Collaborations between Industry and Academia

Speaker to be Announced

Scott Plevy, Janssen, USA
Preventing IBD through Disease Interception

Chas Bountra, University of Oxford, UK
Big Data in Pharma-Academic Collaborations

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, JANUARY 18

Departure